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Background: Quantitative methylation-specific PCR (qMSP) analysis for determining the methylation status of
(candidate) tumor suppressor genes has potential as objective and valuable test to triage high-risk human
papillomavirus (hrHPV) positive women in cervical screening. Particularly combined methylation analysis of a panel
of genes shows most promising clinical performance, with sensitivity levels that equal or exceed that of cytology.
However, the wide application of such methylation marker panels is hampered by the lack of effective multiplex
assays allowing simultaneous methylation detection of various targets in a single reaction. Here, we designed and
analyzed a multiplex qMSP assay for three genes whose methylation was previously found to be informative for
cervical (pre)cancer (i.e. CADM1, MAL and hsa-miR-124-2) as well as a reference gene β-actin. Based on our
experience, we discuss the optimization of the parameters that provide a practical approach towards multiplex
qMSP design.
Methods: Primers and PCR reagents were optimized for multiplex qMSP purposes and the resulting assay was
analytically validated on serial dilutions of methylated DNA in unmethylated DNA, and compared with singleplex
counterparts on hrHPV-positive cervical scrapings.
Results: Upon optimization, including primer redesign and primer limiting assays, the multiplex qMSP showed the
same analytical performance as the singleplex qMSPs. A strong correlation between the obtained normalized ratios
of the singleplex and multiplex qMSPs on cervical scrapes was found for all three markers: CADM1 (R2=0.985),
MAL (R2=0.986) and hsa-miR-124-2 (R2=0.944).
Conclusion: Multiplex qMSP offers a promising approach for high-throughput diagnostic analysis of the
methylation status of multiple genes, which after proper design and validation can be equally specific, sensitive and
reproducible as its singleplex versions.
Keywords: Cervical cancer, HPV testing, DNA methylation, Promoter, CADM1, MAL, hsa-miR-124-2, Multiplex qMSP,
Primer/probe design, 7500Fast ABI systemBackground
Persistent infection with high-risk human papillomavirus
(hrHPV) types is causally involved in the development
of both squamous cell carcinoma (SCC) and adenocar-
cinoma (AdCA) of the cervix [1,2]. Testing for hrHPV
in cervical screening programs results in earlier detection
of clinically relevant cervical lesions (high grade cervical* Correspondence: r.steenbergen@vumc.nl
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distribution, and reproduction in any mediumintraepithelial neoplasia or cancer (CIN2+) than cytology
[3,4]. This provides a higher reassurance of low cervical
cancer risk in test negative women [4,5]. However, only a
fraction of hrHPV positive women will have or develop
CIN2+, arguing for the use of additive disease markers to
distinguish the subgroup of women having a high likeli-
hood of high-grade disease in need of further gynecologic
examination.
Epigenetic silencing of tumor suppressor genes by
DNA methylation in cervical (pre)cancers has beenntral Ltd. This is an Open Access article distributed under the terms of the
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tial applicable to both clinician-collected cervical scrape
samples and self-collected cervico-vaginal specimens
[6-9]. Methylation of CpG islands within promoter regions
of genes and microRNAs such as CADM1, MAL, and
hsa-miR-124-2, reflects mechanistically relevant events
for cervical carcinogenesis [8,10,11]. Until now, DNA
methylation of many genes has been analyzed, often by
quantitative methylation-specific PCR (qMSP), on tissue
and/or cervical scrape samples (reviewed by Wentzensen
et al. [12]). Recent studies indicate that most optimal
sensitivity rates for CIN2+ can only be obtained by test-
ing for a combination of methylation markers [13-16].
However, determining the methylation status of multiple
methylation markers separately is time consuming and
relatively large amounts of sample material are needed.
Multiplexing allows for more methylation targets to be
analyzed using a single aliquot of sample material with
potential for reducing target-to-target differences and
monitoring sample adequacy for PCR purpose by an in-
ternal reference gene, thereby saving material, time and
costs and improving quality control.
Here, we describe the consecutive experimental steps
to set up a multiplex qMSP for CADM1, MAL and hsa-
miR-124-2 and the reference gene β-actin (ACTB) with
equal analytical performance as the individual singleplex
qMSP assays. Following analytical validation, a proof of
concept analysis was performed on cervical scrapings.
The findings provide a practical guide for qMSP design
and demonstrate that multiplex qMSP can be used for
high-throughput diagnostic analysis, without the risk of
a decrease in assay performance.Methods
Cell cultures
Primary human foreskin keratinocytes (EKs) and the
cervical cancer cell line SiHa were cultured as described
previously [17].Cervical scrapings
Cervical scrapings were obtained from the population-
based cervical screening trial POBASCAM, registered as
ISRCTN20781131 [18]. We randomly selected 33 cervical
scrapings of GP5+/6+−PCR hrHPV-positive women with
normal cytology without evidence of CIN2+ up to the next
screening round after 5 years (i.e., two had histologically
CIN1, 31 had histologically no CIN) and 12 scrapings clas-
sified as mild dyskaryosis or worse of hrHPV-positive
women with CIN3 (n=11) or SCC (n=1) diagnosed within
18 months of follow-up. This study followed the ethical
guidelines of the Institutional Review Board of the VU
University Medical Center.DNA extraction, HPV typing and bisulfite modification
DNA was isolated from cervical scrapes using Nucleo-
Spin 96 Tissue kit (Macherey-Nagel) and a Microlab
Star robotic system (Hamilton) according to manufac-
turers' instructions. Genomic DNA from cell cultures
was isolated with UltraPureTM Phenol:Chloroform:Isoa-
myl Alcohol (Invitrogen Life Science Ltd, Carlsbad, CA
USA). HPV detection and genotyping was performed
using the general primer GP5+/6+−PCR enzyme im-
munoassay, followed by reverse line blot analysis [19].
Furthermore, genomic DNA from tissue specimens and
cell lines (0.5 to 2 μg) were subjected to bisulfite treat-
ment with the EZ DNA Methylation KitTM (Zymo Re-
search, Orange, CA, USA). Standard curves were
generated by spiking methylated DNA from the SiHa
cell line in unmethylated DNA from EKs in order to
obtain a serial dilution of 50 ng to 0.25 ng methylated
DNA in a total of 50 ng of DNA.
Quantitative MSP (qMSP) analysis
For the amplification reaction 2.5 μl bisulfite treated
DNA (50 ng) was added to 10 μl amplification mix con-
taining 1x Quantitect Probe mix (Qiagen, Leusden, The
Netherlands), various primer concentrations (50 – 400
nM) and 200 nM of the hydrolysis probe. Sequences of
primers and hydrolysis probes are available on request.
Amplification and real-time measurement was per-
formed in the 7500Fast ABI system (Applied Biosystems,
Foster City, CA, USA), using the following conditions;
15 min at 95°C followed by 40 cycles of 15 s at 95°C and
1 min at 60°C.
Multiplex qMSP analysis
Multiplex qMSP analysis was mainly done using Quanti-
Tect Muliplex mix (Qiagen), unless specified otherwise.
The other master mixes tested were EpiTect MethyLight
mix (Qiagen), iQ Multiplex Powermix (Bio-Rad, Veenen-
daal, The Netherlands) or Genotyping Master Mix (Ap-
plied Biosystems). For the amplification reaction, 2.5 μl
bisulfite treated DNA (50 ng) was added to 10 μl amplifi-
cation mix containing 1x Multiplex mix, 400 nM of MAL
and hsa-miR-124-2 primer, 200 nM of ACTB and CADM1
primer, and 200 nM hydrolysis probe of each target with
the following conditions; 10 or 15 min at 95°C followed
by 40 cycles of 15 s or 60 s at 94°C or 95°C and 60 s
or 90 s at 60°C, depending on the buffer system used.
Data analysis
Methylation values were normalized to the reference
gene ACTB using the comparative Cq method (2-ΔCQ)
[20]. The amplification efficiencies were calculated by
E=(10(−1/Slope)-1)×100% for all serial dilutions [21]. Cor-
relations (R2) of the serial dilutions and normalized
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cervical scrapings were determined using MicrosoftW
Office Excel 2003 (SP3).
Results
Parameters important for multiplex qMSP design
The various parameters important for multiplex qMSP
development, as summarized in Figure 1, are described
in the following section.
First, multiplex qMSP development requires the selec-
tion of dyes that give a good spectral separation to avoid
overlap of the signals of different targets. The ABI7500-
Fast Real-Time PCR System, used in this study, has five
different channels. One channel is used by ROX (emis-
sion maximum at 602 nm), a dye present in the master
mix to correct for pipetting errors (passive reference),
leaving four channels to be used for target detection. In
this study, FAM (520 nm), JOE (548 nm), Dragon FlyFigure 1 Practical approach to multiplex qMSP development. PartiallyOrange (DFO; 576 nm) and CY5 (650 nm) were used. It
should be taken into account that the fluorescence inten-
sities (ΔRn) differ between these four dyes, which can
affect the Quantification Cycle (Cq) values.
The second step involves the selection of primer pairs
for all targets that display nearly identical annealing
temperatures in order to ensure similar amplification
efficiencies. Singleplex qMSPs for CADM1, MAL and
hsa-miR-124-2 have been described previously [9,11],
though primers differed in their annealing tempera-
tures as determined using Primer Express version 3.0
(Applied Biosystems). Whereas the annealing tempera-
tures of the hsa-miR-124-2 primers and primers of
ACTB were comparable (58.2-59.9°C), the CADM1 and
MAL primers had lower annealing temperatures (54-57°C).
When testing these primer pairs in a multiplex qMSP at an
annealing temperature of 60°C, no linear amplification
curves were seen for CADM1 and MAL (Figure 2A, B).adapted from Henegariu [22].
Figure 2 Standard curves of CADM1 and MAL in a multiplex qMSP with ACTB* tested on a serial dilution series of methylation positive
SiHa DNA in methylation negative DNA of primary keratinocytes. Standard curve of CADM1 (A) and MAL (B) with the previously described
primers 9. CADM1 (C) and MAL (D) primers with nearly identical annealing temperatures as ACTB primers. For the dilution series the PCR
efficiencies were calculated by E=(10(−1/Slope)-1)×100%. The qPCR efficiencies increased from 76% to 87% for CADM1 and 52% to 105% for MAL.*)
Multiplex qMSP was performed with an ACTB primer concentration of 200 nM.
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obtain primers with annealing temperatures comparable to
that of ACTB and hsa-miR-124-2. For primer (re)design
the following parameters were taken into account: 1) inclu-
sion of as many CpG sites as possible (at least two), prefer-
ably at the 3’-end [23]; 2) maximum amplicon length of
150 bp, based on the fact that DNA is strongly degraded
upon bisulfite conversion; 3) minimization of formation of
intramolecular interactions within the primer (hairpins),
dimerization with itself (self-dimers) or with primers for
the other targets (cross-dimers) and 4) a methBLAST
search at http://medgen.ugent.be/methBLAST/ to ensure
target specificity of primers.
Following primer redesign, the PCR efficiencies
increased from 75% to 95% and 52% to 105% for
CADM1 and MAL, respectively, in the multiplex qMSP
(Figure 2C, D).
Next a primer limiting assay was performed to deter-
mine at which primer concentration an early plateau
phase is reached, resulting in a lower ΔRn, with an un-
changed Cq. This optimization is required because amp-
lification of most abundant targets may result in
depletion of the dNTPs present in the reaction mixture,
thereby hampering amplification of other targets
(Figure 3A). To determine the lowest primer concentra-
tion that does not affect the Cq value for all four targets,
singleplex qMSP was performed with different primer
concentrations, ranging from 400 nM to 50 nM. For
ACTB the same Cq was obtained at primer concentra-
tions of 400, 300 and 200 nM, with a lower ΔRn
observed at 300 and 200 nM (Figure 3B). The Cqincreased at a primer concentration of 100 nM. Hence,
200 nM was selected as the minimum concentration for
amplifying ACTB in a multiplex reaction. When an
ACTB-MAL multiplex qMSP was performed with an
ACTB-primer concentration of 200 nM, MAL is effi-
ciently amplified (Figure 3C). For CADM1, MAL and
hsa-miR-124-2 the minimum primer concentrations were
200 nM, 400 nM and 400 nM (Figure 3D-F), respectively.
To optimize the multiplex qMSP analysis, various
commercially available TaqMan buffer systems were
compared. For this purpose, the EpiTect MethyLight
Mix (Qiagen), the iQ Multiplex Powermix (Bio-Rad), the
Genotyping Master Mix (Applied Biosystems) and the
QuantiTect Multiplex Mix (Qiagen) were tested on 50
ng of bisulfite treated SiHa DNA, which is positive for
CADM1, MAL and hsa-miR-124-2 methylation. The
reactions were performed in triplicate using multiplex
qMSP conditions as outlined in the Materials and Methods
section. The fluorescence data with the different TaqMan
buffer systems were collected to determine the Cq at a
threshold of 0.01 and the highest maximum fluorescent sig-
nal (ΔRn at Cq=40). The most optimal TaqMan buffer sys-
tem for multiplex qMSP should have a low Cq value
combined with a high ΔRn. The Genotyping Master Mix
gave the highest Cq values combined with the highest ΔRn
values, indicating that this master mix is not ideal for multi-
plex qMSP (Table 1). Reactions that used iQ Multiplex
Powermix revealed the highest maximum ΔRn. However,
as the minimum ΔRn (Cq=0) was relatively high, the
threshold needed to be adjusted to 0.1. This adjustment
resulted in the lowest Cq values, which could not be
Figure 3 Primer-limiting assays for ACTB, CADM1, MAL and hsa-miR-124-2. (A) Amplification curve of MAL in a multiplex qMSP with ACTB.
When ACTB-primers are used at a concentration of 400 nM, there is little to no amplification of MAL, which could be due to dNTP depletion by
ACTB. (B) The minimum primer concentration of ACTB was 200 nM. (C) When the ACTB-primer concentration was lowered to 200 nM MAL
amplification was not hampered. The minimum primer concentration was 200 nM for CADM1 (D), and 400 nM for MAL (E) and miR-124-2 (F).
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tion mixtures due to differences in thresholds. With the
iQ Multiplex Powermix the amplification curves for all
targets had relatively small exponential phases, resulting
in a small range for determining the most optimal
threshold. The Cq and ΔRn values obtained with EpiTect
Methylight and QuantiTect Multiplex buffer systems were
comparable. Due to the convenience of the presence of
the passive reference ROX in the QuantiTect Multiplex
buffer, which was not in the EpiTect Methylight mix for
multiplexing on a ABI7500, the QuantiTect Multiplex mix
was used in subsequent optimization experiments.
Analytical validation of the multiplex qMSP
Using a serial dilution series of methylated DNA in
unmethylated DNA, the performance of the designedmultiplex qMSP was compared to the singleplex qMSP
(Figure 4). The correlation (R2) for all the singleplex and
multiplex qMSPs were higher than 0.99, indicating high
linearity (Figure 4A-C). Whereas the Cq values, when
determined at a threshold of 0.01, differed between single-
plex and multiplex qMSP, same Cq values were obtained
when adjusting the thresholds, resulting in overlapping
standard curves. In addition, high efficiencies, ranging
from 87% to 94% for singleplex qMSP and 92% to 109%
for multiplex qMSP, were found. This indicates that there
is no qMSP inhibition upon multiplexing ACTB, CADM1,
MAL and hsa-miR-124-2. The high reproducibility of the
multiplex qMSP is demonstrated in Additional file 1,
showing the results of 10 independent multiplex qMSP
runs on a serial dilution of 50 to 0.05 ng of methylated
DNA in a background of unmethylated DNA.
Table 1 Multiplex qMSP results using different TaqMan buffer systems*
TaqMan Buffer System








ACTB Cq 27.19±0.093 26.712±0.072 28.448±0.933 27.972±0.032
ΔRn 0.244±0.004 2.655±0.003 0.791±0.090 0.170±0.003
CADM1 Cq 28.216±0.130 27.485±0.038 28.463±0.341 28.888±0.103
ΔRn 0.267±0.006 2.722±0.038 1.160±0.056 0.182±0.004
MAL Cq 26.432±0.170 25.593±0.030 29.499±0.837 26.759±0.053
ΔRn 0.371±0.022 2.662±0.026 1.003±0.203 0.282±0.023
Hsa-miR-124-2 Cq 27.062±0.164 25.861±0.144 29.330±0.826 27.545±0.021
ΔRn 0.630±0.010 6.505±0.029 0.691±0.125 0.514±0.014
* Triplicate analyses of 50 ng of bisulfite treated SiHa DNA. Mean values are indicated ± standard deviations.
** Threshold 0.1.
Figure 4 High linearity between singleplex and multiplex analysis on serial dilutions of methylated DNA (SiHa) in unmethylated DNA
(EK). The multiplex reactions showed comparable efficiencies as the singleplex reactions for CADM1 (A), MAL (B) and hsa-miR-124-2 (C). Same
thresholds were used in singleplex and multiplex qMSP, resulting in different Cq values for all targets. When adjusting the thresholds, the same
Cq values can be obtained, resulting in overlap of the standard curves.
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Eventually, the multiplex qMSP was tested on 45
hrHPV-positive cervical scrapings. The normalized ratios
of singleplex qMSPs of the cervical scrapings correlated
strongly to those of multiplex qMSP for all three mar-
kers (Figure 5A-C). Correlation coefficients were as fol-
lows: R2 = 0.985, R2 = 0.986 and R2 = 0.944 for CADM1,
MAL and hsa-miR-124-2, respectively. Of note, the same
Cq ratios between singleplex and multiplex qMSP could
be obtained when adjusting the threshold settings for all
three markers and ACTB. These results indicate that the
developed multiplex qMSP assay shows an equal per-
formance in detection methylation in these samples as
the singleplex qMSPs.Figure 5 Correlation between the ΔCq values obtained with singleple
0.985, 0.986 and 0.944 for CADM1 (A), MAL (B) and hsa-miR-124-2 (C), resp
due to differences in set thresholds.Discussion
Here, we describe the development of a multiplex qMSP
analysis for the methylation markers CADM1, MAL and
hsa-miR-124-2 and the reference gene ACTB. To obtain
a multiplex qMSP, primers were adjusted to acquire
identical annealing temperatures to enable similar ampli-
fication efficiencies for all targets. Multiplex TaqMan
buffer systems were compared and primer concentra-
tions were limited to allow efficient amplification of all
targets. Analytical validation using a dilution series of
methylated DNA spiked with unmethylated DNA
showed an equal performance of the multiplex qMSP
compared to the individual singleplex qMSPs. Moreover,
the multiplex qMSP was found to be very robust,x and multiplex qMSP. The R2 values for the three markers were
ectively. The ΔCq values between singleplex and multiplex qMSP differ,
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ments. Further evaluation on cervical scrapings revealed a
high correlation between the obtained normalized ratios of
the singleplex qMSPs and the multiplex qMSP. Based on
our experience obtained by optimizing a multiplex qMSP,
a guideline is designed (Figure 1), describing the consecu-
tive experimental steps for multiplex qMSP set up.
Major advantages of multiplexing are less hands-on
time and less amounts of DNA required to determine
the methylation status of multiple methylation markers
as compared to running multiple singleplex analyses.
Moreover, freeze-thawing of bisulfite modified DNA,
which is inherent to repetitive singleplex analysis may
degrade the single-stranded DNA, resulting in increased
Cq values [24]. Another advantage is the improved data
quality, because the methylation marker is normalized to
the reference gene present in the same reaction, thereby
reducing the potential negative impact of for example
pipetting errors when the reference gene is tested in a
separate reaction. These features of multiplex qMSP are
extremely beneficial for molecular diagnostics.
Both the EpiTect Methylight and QuantiTect Multiplex
Mix buffer systems could be used for multiplex qMSP.
Other TaqMan buffer systems, such as the Genotyping
Master Mix and the iQ Multiplex Powermix are less favor-
able for multiplex analysis, due to high Cq values/low
ΔRn or low linear phase amplifications. With this opti-
mized multiplex qMSP, the normalized ratios obtained
from cervical scrapings correlated strongly with those of
the individual singleplex assays.
The development of a multiplex qMSP has been
described before in a study on colorectal cancer [25]. In
this study the dyes, FAM, Hex CY5 and Texas Red were
used, the latter of which prohibits the use of ROX as a
passive reference to normalize for non-PCR-related fluc-
tuations in fluorescence signal. Moreover, it is unknown
whether the relatively high concentration of ACTB pri-
mers used, affected amplification of the other targets, as
no primer limiting assays were described. Others have
proposed the combination of a circularizing oligonucleo-
tide probe, the so-called target-selection-padlock probes,
with microarray technology as a high-throughput ap-
proach for DNA methylation detection [26]. However,
with this technique hundreds of genes are analyzed,
while only several methylation markers are needed for
diagnostic use. Another promising multiplex technique
is the recently described quantitative allele-specific real-
time target and signal amplification (QuARTS), which
showed to be highly sensitive [27]. Future studies will
show its potential value in a diagnostic setting.
The analytical performance of the multiplex qMSP could
potentially be further improved by the incorporation of
Locked Nucleic Acids (LNAs) in primers and/or hydrolysis
probes [28], as has been described for singleplex MGMT[29] and CADM1 [30] qMSPs. In analogy to its use for
improved DNA mutation analysis (as was reviewed by
[31]), peptide nucleic acid (PNA) hybridization probes, in
which the sugar-phosphate backbone of DNA is replaced
by a pseudopeptide and very stable heteroduplexes can be
formed. This would prevent amplification of unmethylated
DNA, thereby enhancing the analytical performance of
qMSP. The impact of such modification on the clinical
performance of methylation analysis warrants further
evaluation.
The multiplex qMSP described here was performed on
an ABI7500 Fast Real-Time PCR System, which supports
multiplexing of five targets, when ROX is not present in
the buffer system. In principle, even more methylation
markers can be incorporated into the multiplex qMSP,
when other devices will be used, such as the ViiATM
7 Real-Time PCR System (Applied Biosystems) or the
LightCycler 480 (Roche), which support multiplexing of
six targets. We were however unable to develop a multi-
plex qMSP on the ABI7900HT Fast Real-Time PCR Sys-
tem, which may be related to the differences in detection
systems.
The CADM1, MAL, hsa-miR-124-2 multiplex methyla-
tion assay described here may serve as a triage test for
hrHPV-positive women in population-based screening.
We recently demonstrated that combined CADM1 and
MAL promoter methylation analysis on physician-taken
cervical scrapings of hrHPV-positive women was at least
equally discriminatory for high-grade CIN as cytology
or cytology combined with HPV16/18 genotyping [14].
Futhermore, these methylation markers are applicable
to self-collected cervico-vaginal lavage specimens for
colposcopy triage of hrHPV-positive women (Hesselink
et. al, unpublished observations) and are currently tested
prospectively [32].
Conclusion
In summary, multiplex qMSP is a high-throughput, quan-
titative assay to analyze multiple methylation markers in a
single reaction. It showed to be equally specific, sensitive
and reproducible as its singleplex versions. Due to the ma-
terial saving capacity, the multiplex qMSP may allow ana-
lysis of samples with limited methylated DNA content,
such as bodily fluids, like urine, blood or sputum. Multi-
plex qMSP can be applied to cervical scrapes and self-
collected specimens and used as a triage tool for detection
of high-grade cervical lesions in hrHPV-positive women.
Additional file
Additional file 1: Reproducibility of multiplex qMSP. Serial dilutions
of methylated DNA (SiHa) spiked with unmethylated DNA (EK) in order to
obtain a serial dilution of 50 ng to 0.25 ng methylated DNA in a total of
50 ng of DNA, showed high reproducibility when testing the multiplex
qMSP in 10-fold.
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